Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Analyst downgrades Salesforce to a sell rating due to slowing growth in key segments and AI posing a risk to revenue model.

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $97.94 which represents a slight increase of $2.39 or 2.50% from the prior close of $95.55. The stock opened at $96.63 and touched a ...

Merck & Co. Inc. closed 27.25% short of its 52-week high of $134.63, which the company reached on June 25th.

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...

Analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Merck & Co., Inc. in a research report issued to clients and investors on Friday, January 24th. Leerink Partnrs analyst D.

In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Merck & Co Inc (MRK) stock saw a decline, ending the day at $95.55 which represents a decrease of $-1.08 or -1.12% from the prior close of $96.63. The stock opened at $96.79 and touched a low of ...